Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0MVGDP
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
IBI-3005
|
|||||
| Synonyms |
IBI 3005; IBI3005
Click to Show/Hide
|
|||||
| Organization |
Innovent Biologics, Inc.
|
|||||
| Drug Status |
Phase 1
|
|||||
| Indication |
In total 1 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
Undisclosed
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
Epidermal growth factor receptor (EGFR); Receptor tyrosine-protein kinase erbB-3 (HER3)
|
Antigen Info | ||||
| Payload Name |
Camptothecin analog
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Undisclosed
|
|||||
